Trial Profile

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb7195

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AIMab 7195 (Primary) ; AIMab 7195 (Primary)
Indications Allergic asthma; Hypersensitivity
Focus Pharmacokinetics
Sponsors Xencor

Most Recent Events

05 Jan 2018 According to a Xencor media release, data from the subcutaneous Phase 1b study were announced in November 2017.
09 May 2017 According to a Xencor media release, top-line data is expected in 2017.
01 May 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com